Monday, October 1, 2018

Dr Reddy#39;s Labs terminates Armis Biopharma#39;s licence for its investigational antibacterial product

Dr Reddy#39;s Labs terminates Armis Biopharma#39;s licence for its investigational antibacterial product According to a press release issued by the Indian drug maker, as a result of the termination, Dr Reddy#39;s has regained worldwide rights to DFA-02, and is currently evaluating its options to take the programme forward.

from Moneycontrol Business News https://ift.tt/2Iutlyu
at
Labels: , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

LTIMindtree Q4 Preview: Lower pass-through revenue seen impacting growth marginally

A compilation of estimates suggests the company#39;s Q4 FY24 net profit is projected to decline by 2.2 percent quarter on quarter to Rs 1,1...